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Abstract
Objective
The functionality of high-density lipoprotein (HDL) is impaired in chronic ischaemic heart
failure (HF). However, the relationship between HDL functionality and outcomes in acute
HF (AHF) has not been studied. The present study investigates whether the metrics of HDL
functionality, including HDL cholesterol efflux capacity and HDL-associated paraoxonase
(PON)-1 arylesterase (AE) activity are associated with hospital mortality in AHF patients.
Methods and Results
The study was performed as a prospective, single-centre, observational research on 152
patients, defined and categorised according to the ESC and ACCF/AHA Guidelines for HF
by time of onset, final clinical presentation and ejection fraction. The mean age of the
included patients (52% female) was 75.2 years (SD 10.3) and hospital mortality was 14.5%.
HDL cholesterol efflux capacity was examined by measuring the capacity of apoB depleted
serum to remove tritium-labelled cholesterol from cultured macrophages. The AE activity of
the HDL fraction was examined by a photometric assay. In a univariable regression analy-
sis, low cholesterol efflux, but not AE activity, was significantly associated with hospital mor-
tality [odds ratio (OR) 0.78, 95% confidence interval (CI) 0.64–0.96, p = 0.019]. In
multivariable analysis progressively adjusting for important clinical and laboratory parame-
ters the association obtained for cholesterol efflux capacity and hospital mortality by univari-
able analysis, despite a stable OR, did not stay significant (p = 0.179).
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Conclusion
Our results suggest that HDL cholesterol efflux capacity (but not AE activity) contributes to,
but is not an independent risk factor for, hospital mortality in AHF patients. Larger studies
are needed to draw firm conclusions.
Introduction
Clinical and epidemiological studies demonstrated an inverse relationship between high-den-
sity lipoprotein cholesterol (HDL-cholesterol) levels and cardiovascular disease (CVD) [1].
However, recent studies provided evidence against HDL-cholesterol as a potential therapeutic
target. Along these lines, a study using the Mendelian randomisation approach failed to reveal
an association between genetic variants that raise HDL-cholesterol plasma concentrations and
a lower risk of cardiovasuclar events [2]. Furthermore, pharmacological interventions aimed at
raising HDL-cholesterol levels failed to reduce cardiovascular events [3, 4]. Determination of
HDL particle concentrations and HDL subclasses as well as determination of HDL functional-
ity have proved more appropriate to test and quantify the beneficial atheroprotective properties
of HDL [5, 6]. HDL-mediated atheroprotection has been ascribed to the attenuation of endo-
thelial adhesion molecule expression, protection of low-density lipoprotein (LDL) from oxida-
tion, inhibiton of inflammatory response in macrophages, stimulation of endothelial nitric
oxide production and promotion of vasodilatation [7–11]. The best-studied protective activity
of HDL is the promotion of reverse cholesterol transport, a dynamic process by which HDL
removes cholesterol from the periphery for delivery back to the liver for excretion [12]. Recent
studies provided strong evidence that HDL-cholesterol efflux capacity, the first step in the pro-
cess of reverse cholesterol transport, is inversely associated with incident coronary heart events,
independent of established cardiovascular risk factors [13].
HDL-associated paraoxonase-1 (PON-1) emerged as an important mediator of many pro-
tective functions of HDL [7, 14, 15]. In line with this, PON-1 knockout mice show an enhanced
susceptibility for developing atherosclerosis [16], whereas PON-1 overexpressing mice are pro-
tected from the development of atherosclerosis and exhibit reduced systemic measures of oxi-
dation [17]. Reduced systemic PON-1 activity in humans, as monitored by serum arylesterase
(AE) activity levels, was found to be accompanied by increased systemic oxidative stress and to
predict an increased risk for major adverse cardiac events [18].
Heart failure (HF) can be defined as an abnormality of cardiac structure or function leading
to failure of the heart to deliver oxygen at a rate commensurate with the requirements of the
metabolising tissues, despite normal filling pressures (or only at the expense of increased filling
pressures) [19, 20]. Acute heart failure (AHF) is the term used to describe the rapid onset of, or
change in, symptoms and signs of HF [20]. Previous studies showed that low HDL-C levels
were associated with increased mortality and adverse prognosis in HF patients [21, 22]. Impor-
tantly, both the antioxidative and cholesterol efflux capacities of HDL were found to be reduced
in HF patients when compared with healthy controls [18, 23].
In the present study we examined whether HDL-cholesterol efflux capacity and HDL-asso-
ciated PON-1 AE activity are risk factors for hospital mortality in AHF patients. To get an inte-
grated measure of HDL quantity and quality, we assessed the metrics of HDL functionality in
apoB-depleted serum. We found that HDL-cholesterol efflux capacity (but not AE activity),
contributes to, but is not an independent risk factor for hospital mortality in AHF patients.
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Materials and Methods
Study design and Patients
The AHF study was performed as a prospective, single-centre, observational research study
including consecutive adult white hospitalised AHF patients. The study was approved by the
local Ethics Committee of the University Hospital Centre Sisters of Charity, Zagreb, Croatia
(UHC SC) as well as by the local Ethics Committee of the Medical University of Graz. Written
informed consent was obtained from each patient in compliance with Good Clinical Practice,
and the investigation conforms with the principles outlined in the Declaration of Helsinki [24].
In total, 152 patients were recruited from the Emergency Department from November 2013 to
February 2015. The patients were defined and categorised according to the ESC and ACCF/
AHA Guidelines for HF by time of onset, final clinical presentation and ejection fraction (EF)
[19, 20, 25]. All patients were treated in accordance with standard ESC Guidelines for AHF
[20, 25].
Laboratory assays
Blood samples for routine laboratory assays were obtained from the AHF patients at admission
to the hospital. The blood was collected in 6 mL tubes, VACUETTE1 Z Serum Clot Activator
(Greiner Bio-one GmbH, Kremsmuenster, Austria) with a special coating on the internal wall
of the tubes containing microscopic silica particles to prevent clot formation by surface activa-
tion. Serum creatinine, urea, total plasma cholesterol, LDL cholesterol, HDL-cholesterol and
triglycerides were measured using a Beckman Coulter instrument AU 2700, 2007 (Brea, CA,
SAD) and Architect c8000, Abbott 2013 (Chicago, IL, SAD). Glomerular filtration rate (GFR)
was calculated as described [26]. The serum aliquots were stored and transported at -80°C.
ApoB-depletion of serum
ApoB-depleted serum was prepared by the addition of 40 μL polyethylene glycol (20% in 200
mmol/L glycine buffer) to 100 μL serum. The samples were incubated at room temperature for
20 minutes and the supernatant was recovered after centrifugation (10.000 rpm, 20 minutes,
4°C) as described [27].
Measurements of HDL cholesterol efflux capacity
HDL cholesterol efflux capacity was quantified using a validated ex vivo assay that measures
the ability of apolipoprotein-B depleted serum to mobilize cholesterol from cholesterol-laden
macrophages [23, 28–31]. J774 cells, a mouse macrophage cell line [32], were plated and
labeled for 24 hours with 1 μCi/mL 3H-cholesterol (Perkin Elmer, Boston, MA, USA). J774
cells express very low levels of ATP-binding cassette transporter A1 (ABCA1), an important
pathway of cholesterol efflux from macrophages. To upregulate ABCA1, cells were stimulated
for 6 hours with serum-free DMEM containing 0.3 mmol/L 8-(4-chlorophenylthio)-cyclic
AMP (Sigma, Darmstadt, Germany). After this incubation period, cells were washed and 3H-
cholesterol efflux was determined by incubating cells with 2.8% apoB-depleted serum for 4
hours as described [28]. Liquid scintillation counting was used to quantify the efflux of radioac-
tive cholesterol from the cells. The quantity of 3H-cholesterol incorporated into cellular lipids
was assessed by means of isopropanol extraction of 3H-cholesterol content of J774 cells not
exposed to the patients' serum. The percent efflux was calculated by the following formula:
[(microcuries of 3H-cholesterol in media containing 2.8% apolipoprotein B–depleted serum—
microcuries of 3H-cholesterol in serum-free mediums)microcuries of 3H-cholesterol in cells
before the efflux step] × 100. All steps were performed in the presence of 2 μg/mL of the acyl
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coenzyme A cholesterol acyltransferase inhibitor Sandoz 58–035 (Sigma, Darmstadt, Ger-
many). The values shown represent the means of two independent assays performed in dupli-
cates. To correct for interassay variation across plates, we included a serum control on each
plate, and we normalised the values for patient serum samples to this value in the subsequent
analyses. The intra-assay coefficient of variation was 7.1% and the interassay coefficient of vari-
ation was 6.8%.
AE activity assay
The Ca2+-dependent AE activity in apoB-depleted serum was determined using a photometric
assay with phenylacetate as the substrate, as previously described [33].
Statistical analysis
Categorical data are presented as absolute and relative frequencies, continuous data are pre-
sented as mean and SD or as median and range (minimum to maximum) according to distri-
bution. The Pearson correlation coefficients were calculated to assess the correlation of AE
activity and cholesterol efflux capacity with the clinical and laboratory parameters. To study
the impact of AE activity and cholesterol efflux capacity on hospital mortality, a univariable
logistic regression analysis was performed. In addition, the impact of the following variables on
hospital mortality was analysed: age, gender, body mass index (BMI), hypertension, diabetes
mellitus type 2, mean arterial pressure (MAP), New York Heart Association Functional Classi-
fication (NYHA) classes, ejection fraction (EF), high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides (logarithmic scale)
and GFR. To further explore the relationship of the cholesterol efflux capacity and hospital
mortality, we progressively adjusted for important clinical and laboratory parameters. All vari-
ables that were associated with hospital mortality in the univariable analysis (p 0.02) were
included as potential covariates in a multiple logistic regression model [34]. Forward selection
with a p enter< 0.15 was used and the multicollinearity among covariates was assessed
between these variables using the variance inflation factors (VIF> 4). Goodness of fit was




In this study 152 patients were included, 79 (52%) were female. The mean age of the included
patients was 75.2 years (SD 10.3) and the mean BMI was 28.8 kg/m2 (SD 5.4). Worsening of
chronic HF was present in the majority (69.1%) of the studied patients. Recorded frequent
comorbidities were hypertension (89.5%), metabolic syndrome (55.9%), type 2 diabetes melli-
tus (51.7%), hyperlipidaemia/hypertriglyceridaemia (39.5%) and hypercholesterolaemia
(38.8%). Hospital mortality was 14.5%. The patients' baseline characteristics are presented in
Table 1.
Correlation of HDL cholesterol efflux and HDL-associated PON-1 AE
activity with clinical and laboratory variables
As shown in Table 2, both HDL cholesterol efflux capacity and AE activity were correlated
with total cholesterol, HDL-cholesterol and LDL-cholesterol, as well as with MAP. Further-
more, AE activity correlated with log(triglycerides) and GFR. Neither efflux nor AE activity
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Table 1. Baseline characteristics, biochemical laboratory parameters, comorbidities, and classifica-
tion of AHF patients (n = 152).
Baseline characteristics
Age (years) 75.2 (10.3)
Gender Female 79 (52%)
Body Weight (kg) 82.9 (19.9)
BMI (kg/m2) 28.8 (5.4)
Waist Circumference (cm) 111.2 (17.7)
MAP (mmHg) 105.4 (21.9)
EF (>40%)* 74 (52.1%)
NYHA class 2 11 (7.2%)
NYHA class 3 83 (54.6%)
NYHA class 4 58 (38.2%)
Biochemical laboratory parameters
Triglycerides (mmol/L) a 1.1 [0.5–4.3]
Total Cholesterol (mmol/L) a 3.8 [1.7–9.1]
HDL-cholesterol (mmol/L)a 1.0 [0.3–3.6]
LDL-cholesterol (mmol/L) a 2.3 [0.8–6.3]
GFR (ml/min/1.73 m2) 50.9 [15.0–105.7]
Comorbidities
Hypertension 136 (89.5%)
Type 2 Diabetes Mellitus 78 (51.7%)
Hyperlipidaemia 60 (39.5%)
Hypercholesterolemia 59 (38.8%)
Classiﬁcation of acute heart failure by time of onset
Worsening of Chronic Heart Failure 105 (69.1%)
De novo 47 (30.9%)
Final Clinical Presentation
Worsening of Chronic Heart Failure 78 (51.3%)
Acute Coronary Syndrome and HF 23 (15.1%)
Hypertensive AHF 22 (14.5%)
Pulmonary Edema 20 (13.2%)
Isolated Right Side AHF 7 (4.6%)
Cardiogenic Shock 2 (1.3%)
Classiﬁcation of acute heart failure by Ejection Fraction**
HFrEF 83 (57.6%)
HFpEF 61 (42.4%)
Metric, continuous, quantitative variables are presented as mean and standard deviation if normally
distributed and median with interquartile range if skewed. Categorical, qualitative variables are presented
as the absolute and relative frequencies are given as percentage. AHF, Acute Heart Failure; HDL, High-
Density Lipoprotein; HFpEF, Heart Failure with preserved Ejection Fraction; HFrEF, Heart Failure with
reduced Ejection Fraction; LDL, Low-Density Lipoprotein; NYHA, New York Heart Association Functional
Classiﬁcation; GFR, glomerular ﬁltration rate; BMI, Body Mass Index; EF, Ejection Fraction; MAP, Mean
Arterial Pressure
aSI measurements. To convert to mg/dL, multiply TG by 89 and TC, HDL, or LDL by 39.
*Based on measurement for 142 patients
**Based on measurement for 144 patients
doi:10.1371/journal.pone.0157507.t001
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were correlated with BMI or EF. The AE activity and cholesterol efflux capacity were signifi-
cantly correlated with each other (r = 0.43; p< 0.001).
Logistic regression analyses
Univariable analyses showed a significant inverse association of cholesterol efflux capacity, but
not of AE activity, with hospital mortality. A significant inverse association with hospital mor-
tality was also observed for LDL-cholesterol and total cholesterol as well as for BMI and MAP
(Table 3). As expected, higher NYHA class was associated with increased hospital mortality
(Table 3). In contrast, no significant associations with hospital mortality were found for HDL-
cholesterol, log(triglycerides), age, gender, hypertension, diabetes mellitus type 2, EF and GFR
(Table 3).
The multivariable model for hospital mortality is shown in Table 4. The model predictors of
hospital mortality included MAP, NYHA class, LDL-cholesterol and BMI. Although choles-
terol efflux was associated with hospital mortality in univariable analysis, there was no signifi-
cant effect after adjusting for the other factors in the multivariable model (p = 0.179).
Discussion
In the present study we prospectively examined whether metrics of HDL functionality, namely,
HDL cholesterol efflux capacity and HDL-associated PON-1 AE activity, were associated with
hospital mortality in AHF patients. We found an association between low HDL cholesterol
efflux capacity and an increased risk for hospital mortality in AHF patients. A previous study
demonstrated a strong association between low serum AE activity and poor long-term progno-
sis in decompensated systolic HF patients [18]. The lack of impact of AE activity on hospital
mortality in the present study might indicate that decreased AE activity is useful only as a long-
term prognostic marker of adverse cardiac events.
In line with decreased blood pressure, an established risk for hospital mortality [35], a
decreased MAP emerged as an independent predictor of hospital mortality in our AHF cohort.
This also fits with ‘‘reverse epidemiology” which describes the paradoxical association of
decreased BMI, serum total cholesterol levels and blood pressure, respectively, with increased
morbidity and mortality in HF patients [36]. However, high levels of serum urea and creatinine
found to be predictive of hospital mortality in acutely decompensated HF patients [35], did not
associate with hospital mortality in our cohort (not shown). A likely explanation for the lack of
Table 2. Pearson correlation of clinical and laboratory variables with HDL AE activity and cholesterol efflux capacity.
AE activity (μmol/L/min) Cholesterol efﬂux (%)
coefﬁcient p-value coefﬁcient p-value
MAP (mmHg) 0.204 0.013 0.186 0.024
BMI (kg/m2) 0.039 0.637 -0.024 0.769
EF (%) -0.030 0.723 -0.132 0.123
HDL-cholesterol (mmol/L) 0.397 <0.001 0.448 <0.001
LDL-cholesterol (mmol/L) 0.461 <0.001 0.194 0.018
Total cholesterol (mmol/L) 0.570 <0.001 0.318 <0.001
Log(Triglycerides) (mmol/L) 0.328 <0.001 0.154 0.061
GFR (ml/min/1.73 m2) 0.177 0.032 -0.009 0.909
MAP, Mean arterial pressure; BMI, body mass index; EF, ejection fraction; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein; AE,
arylesterase;
doi:10.1371/journal.pone.0157507.t002
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association is the exclusion of patients with creatinine levels higher than 400 μmol/L and those
with severe liver cirrhosis (Child-Pugh B or C). The impact of serum total cholesterol levels on
hospital mortality in our cohort was weak and similar to that found in idiopathic cardiomyopa-
thy patients [37], but in contrast to the strong predicting impact of total cholesterol on hospital
mortality observed in AHF patients with overlapping renal dysfunction [38] or patients with
acute decompensated heart failure [39]. Although low HDL-cholesterol levels were associated
with poor prognosis [22] and increased mortality [21] in HF patients, the HDL-cholesterol
Table 3. Univariable logistic regression analysis of HDL function, clinical and laboratory parameters and hospital mortality.
Variable Category N OR LB UB p-value
Metrics of HDL function
AE (μmol/L/min) 0.995 0.990 1.000 0.069
Cholesterol efﬂux (%) 0.783 0.639 0.960 0.019
Clinical parameters
Age (years) 1.034 0.984 1.09 0.184
Gender male 8/73 Ref.
female 14/79 1.75 0.69 4.45 0.240
BMI (kg/m2) 0.91 0.82 1.00 0.044
Hypertension no 3/16 Ref.
yes 19/136 0.70 0.18 2.703 0.609
Type 2 Diabetes Mellitus no 13/73 Ref.
yes 9/78 0.60 0.24 1.51 0.278
MAP (mmHg) 0.95 0.93 0.98 0.001
NYHA class 2 and 3 7/94 Ref
4 15/58 4.34 1.65 11.42 0.003
EF (%) * 1.00 0.96 1.04 0.861
Laboratory parameters
HDL-cholesterol (mmol/L) 0.38 0.09 1.6 0.186
LDL-cholesterol (mmol/L) 0.54 0.31 0.96 0.035
Total cholesterol (mmol/L) 0.58 0.36 0.91 0.018
Log(Triglycerides) (mmol/L) 0.40 0.12 1.42 0.157
GFR (ml/min/1.73 m2) 0.99 0.97 1.01 0.437
N, number of events / total number of patients in category; OR, odds ratio; LB, lower bound of 95% conﬁdence interval; UB, upper bound of 95%
conﬁdence interval; Ref., reference category; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
*Based on measurment for 142 patients.
doi:10.1371/journal.pone.0157507.t003
Table 4. Multivariable logistic regression analysis of hospital mortality.
OR LB UB p-value
MAP (mmHg) 0.96 0.93 0.99 0.008
NYHA class = 4 4.93 1.67 14.49 0.004
LDL-cholesterol (mmol/L) 0.54 0.30 1.00 0.051
BMI (kg/m2) 0.91 0.82 1.01 0.089
Hosmer-Lemeshow goodness of ﬁt test: p = 0.554, OR, odds ratio; LB, lower bound of 95% conﬁdence
interval; UB, upper bound of 95% conﬁdence interval; MAP, Mean arterial pressure; NYHA, New York
Heart Association Functional Classiﬁcation; LDL, low-density lipoprotein; BMI, body mass index;
doi:10.1371/journal.pone.0157507.t004
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levels had no impact on the hospital mortality in our cohort. The observed discrepancies
between findings in different studies most likely reflect differences in the study populations in
terms of sample size, age and gender, inclusion/exclusion criteria, medication or severity and
nature of the disease.
To our knowledge, our study is the first to investigate the association of HDL cholesterol
efflux capacity with outcome in AHF patients. In a previous study, which compared patients
with ischaemic cardiomyopathy and healthy controls, the cholesterol efflux and anti-oxidative
capacity of HDL emerged as significant independent risk factors for HF [23]. Based on these
findings, one would expect stronger associations of reduced cholesterol efflux capacity and
PON-1 AE activity with hospital mortality in our AHF cohort. However, the patients in the
previous study [23], in contrast to our patients, were exclusively ischaemic cardiomyopathy
patients without clinical signs and symptoms of HF. Additionally, the difference in HDL func-
tionality between patients and healthy control subjects is certainly more pronounced than
among patients with a shared pathology.
The decreased cholesterol efflux capacity in patients with stable CAD [28] and the associa-
tion of decreased cholesterol efflux with incident coronary heart disease (CHD) [29] suggest
that the removal of cholesterol from coronary arteries (and probably circulating leukocytes) is
an important protective activity of HDL. This assumption that HDL quality outperforms HDL
quantity for cardiovascular risk prediction stems from general population studies that focused
on the canonical HDL function of promoting cholesterol efflux from macrophages. A similar
protective role of HDL–mediated efflux might be operative in ischaemic cardiomyopathy
patients, where the cholesterol efflux capacity of HDL was identified as a risk factor for HF
[23]. In contrast, however, in our AHF cohort, the HDL-mediated cholesterol efflux might
have exhibited its protective capacity in hardly a half (45.4%) of the patients who had evident
atherosclerosis. Considering the potency of HDL to remove excess of cholesterol from coro-
nary artery walls [12], a higher HDL efflux capacity might be accompanied by better myocar-
dial perfusion and a concomitantly improved heart performance. Accordingly, it is tempting to
speculate that the association of efflux with mortality would be more pronounced in an AHF
population with a higher percentage of patients with coronary atherosclerosis. Moreover,
HDL-mediated removal of cholesterol from plaques in peripheral arteries may conceivably, by
decreasing peripheral resistance, further contribute to spare or improve the function of the fail-
ing heart.
A more direct beneficial effect of HDL on the function of the failing heart might be
explained by the beneficial effects of HDL on cardiomyocytes, such as attenuation of apoptosis,
improved cell survival and preservation of mitochondrial function [40, 41].
The main study strength is its comprehensive design as a prospective single-centre observa-
tional and non-interventional study, with a highly structured protocol and predefined statisti-
cal analyses. An additional strength is the novel use of HDL functionality as a predictor of
hospital mortality in AHF patients. Serum samples were uniformly collected and assays corre-
spondingly performed, which minimised sample preparation bias. The study included well-
defined patients, thus allowing a comparison with similar populations. However, the overall
sample size was modest and therefore our ability to definitely evaluate the association between
cholesterol efflux capacity and AE activity with overall survival was limited. Furthermore,
although commonly used, the HDL-cholesterol efflux capacity assay may have some limita-
tions: The assay employs murine macrophages thus excluding the contribution of patients’
macrophages to the overall cholesterol efflux capacity. Moreover, apoB-depleted serum con-
tains in addition to HDL various proteins capable of mediating cholesterol efflux, which may
interfere with the contribution of HDL.
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Conclusions
Based on our results obtained by a univariable logistic regression analysis, we conclude that
cholesterol efflux capacity, but not AE activity, is associated with hospital mortality in AHF
patients. In a multivariable logistic regression analysis no significant association of efflux
capacity with hospital mortality was found, suggesting that cholesterol efflux capacity is not an
independent risk factor for hospital mortality in AHF patients. However, larger studies are
needed to draw firm conclusions.
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